Key Drivers
- Liquidity Cushion
- Margin Collapse
- Leverage Burden
AIAI Summary
PRGO should be viewed less as a sales-growth story and more as a margin-and-deleveraging turnaround: the Dermacosmetics sale and $80M-$100M savings program can lift earnings, but weak cough/cold demand, retailer destocking, and heavy leverage mean investors should wait for sustained free-cash-flow improvement before expecting a re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Margin Collapse
- •Leverage Burden
PRGO has solid liquidity and a depressed valuation, but heavy leverage, large intangibles, and persistent losses with negative cash flow make the stock a high-risk turnaround rather than a clear value opportunity.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Support test
- •Failed rebound
Over the last month, PRGO has shifted from a rebound into a short-term downtrend, with lower highs/lows now putting $10.60 support at risk unless it reclaims $11.70.
Rose to $12.26 on 2026-05-06, then slid steadily to $10.61 by 2026-05-15
Sentiment & News
Key News Insights:
- •EPS Beat
- •Sales Pressure
- •Portfolio Streamline
Perrigo delivered a mixed Q1 update, with an EPS beat, weaker sales, portfolio simplification via the Dermacosmetics divestiture, and standout growth in Specialty Care.
The update is modestly supportive for Perrigo due to cost discipline, asset sales, and Specialty Care momentum, but broader demand softness may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings